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The protein Matriptase-2 damaged by a novel missense mutation in the TMPRSS6
gene originates an IRIDA-like phenotype in an African child
This study aimed to investigate a 4-year-old boy of sub-Saharan ancestry
(Mozambique/Angola), presenting with microcytic hypochromic anemia, low
transferrin saturation, normal ferritin, and having a partial response to intravenous
iron treatment (Table 1).
The subject is a -α3.7kb-thalassemia carrier. TMPRSS6 gene was screened for variants by
Next-Generation Sequencing using Nextera XT libraries in a MiSeq platform (Illumina).
Genetic variants found were validated by Sanger sequencing. In silico analyses were
performed in HSF, SIFT, Poly-Phen2 and Missense3D softwares. In order to run a
Missense3D analysis, we predicted a 3D Structure for matriptase-2 in the software
Phyre2.
Hematologic and
biochemical
1-4 years old Patient Iron treatment 
parameters Reference Before After
RBC  (x10^12/L) 3.50–5.30 4.51 4.38
Hb (g/dL) 10.7–15.1 9.8 10.2
Ht (%) 31.0–45.0 31.7 33.1
MCV (fL) 72.0–100.0 70.3 75.6
MCH (pg) 23.8–34.2 21.7 23.3
MCHC (g/dL) 31.6–34.9 30.9 30.8
RDW (%) 11.6–13.9 17.7 16.6
Fe  (µg/dL) 62-68 19 51
TIBC (μg/dL) 228-428 313 273
TSAT (%) 16.0-45.0 6.07 18.68
Ft (μg/L) 30.0-300.0 33.0 242.3
 DNA analysis revealed a novel missense mutation c.871G>A in heterozygosity, in TMPRSS6 exon 8. Additionally, 3
SNPs previously associated with a greater risk of developing iron deficiency anemia (K253E, V736A and Y739Y) were
also identified (Figure 2). At protein level, the novel variant gives rise to the G291S mutation, located in the first CUB1
domain, which suggest it may affect the enzyme activation and substrate recognition (Figure 2).
 In silico analysis indicates the conserved amino acid G291 change may be damaging to the protein stability (Figure 3).
Although IRIDA is noted as an autosomal recessive disease, we infer that, in this case, the result of a digenic inheritance of the novel damaging mutation (c.871G>A; G291S) and 3
common modulating SNPs in the same gene in addition to the co-inheritance of the α-thalassemia allele, may add up to an IRIDA-like phenotype. Further functional studies of the
mutated protein as well as family studies should be conducted.
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Figure 1: Matriptase-2 (circled in blue) regulates
cellular iron export:
(1) Dietary iron and iron recycled from
erythrocytes are stored in enterocytes and
splenic macrophages and are released to the
circulation through ferroportin;
(2) Hepcidin produced by hepatocytes binds
ferroportin and targets the channel for
degradation.
(3) Hepcidin gene (HAMP) expression is positively
regulated by bone morphogenic protein
(BMP)6, which signals through the BMP
receptor (BMPR)-SMAD pathway in a
hemojuvelin-dependent manner. Matriptase-
2 increases cellular iron export by degrading
hemojuvelin to reduce hepcidin production
and thus increase ferroportin2.
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Table 1: Hematologic parameters and iron status of the patient
before and after intravenous iron treatment in comparison to
reference values
Figure 2: Schematic model of matriptase-2. a Structurally, matriptase-2
contains a short N-terminal cytoplasmic domain, a membrane-spanning
region (TM), an SEA domain, 2 CUB domains, three LDLa domains, and a
trypsin-like serine protease domain. Coding region mutations are indicated
by arrows. The novel G291S mutation is highlighted in yellow. Adapted
from Lee et al. 2009 4
Figure 3: Results from in silico analysis showing potential damage to the
protein stability. Results from:
(a) Poly-Phen2 that takes into consideration differences between human
proteins and homologous proteins in other mammals (score = 1.000);
(b) SIFT, that assumes the importance of one amino acid based on its level
of conservation within protein the family;
(c) Missense3D, that perceives the importance of a amino acid based on
3D structure of the whole protein;
(d) Also in Missense3D we can compare, based on the predicted structure
for matriptase-2 obtained in the software Phyre2, with 90% of
confidence, the amino acids alteration consequence in the protein
structure.
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Iron-refractory iron deficiency anemia (IRIDA) is a rare autosomal recessive anemia usually
unresponsive to oral iron intake and partially responsive to parenteral iron treatment 1.
This disease is the result of mutations in TMPRSS6 gene, encoding Matriptase-2, a
transmembrane serine protease that plays a key role in down-regulating hepcidin,
allowing iron bioavailability for erythropoiesis (Figure 1) 1,2.
Once TMPRSS6 is mutated, the corresponding protein is absent or inactive at the
hepatocyte membrane leading to uncontrolled high levels of hepcidin and impaired iron
absorption 3.
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